Back to top

Barclays Remains a Buy on Ascendis Pharma (ASND)

Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma today and set a price target of $345.00. According to TipRanks, Merle is a...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ascendis Pharma A/S (ASND)